Lakewood Amedex Biotherapeutics earnings were N/A for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest LABT earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$923.3k, up 23.9% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, LABT reported annual earnings of -$3.8M, with -20.8% growth.
LABT earnings history
Current Revenue
$0.0
Current Earnings
$0.0
Current Profit Margin
0%
LABT Return on Equity
Insufficient data to display
LABT Return on Assets
Insufficient data to display
Be the first to know when LABT announces earnings.
Lakewood Amedex Biotherapeutics Earnings Reports & History FAQ
What were Lakewood Amedex Biotherapeutics's earnings last quarter?
Lakewood Amedex Biotherapeutics (NASDAQ: LABT) reported Q1 2026 earnings per share (EPS) of -$0.20, up 33.33% year over year. Total LABT earnings for the quarter were -$923.29 thousand. In the same quarter last year, Lakewood Amedex Biotherapeutics's earnings per share (EPS) was -$0.15.
Is Lakewood Amedex Biotherapeutics profitable or losing money?
As of the last Lakewood Amedex Biotherapeutics earnings report, Lakewood Amedex Biotherapeutics is currently losing money. Lakewood Amedex Biotherapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was N/A, a N/A decrease year over year.
What was LABT's earnings growth in the past year?
As of Lakewood Amedex Biotherapeutics's earnings date in Q2 2026, Lakewood Amedex Biotherapeutics's earnings has grown year over year. LABT earnings in the past year totalled N/A.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.